VCs’ take on SVB, plus a new surrogate endpoint for ALS
Assessing results from BioCentury’s survey of VCs on the collapse of SVB, and analysis of FDA’s tofersen panel and draft guidance on accelerated approval
By Jeff Cranmer, Executive Editor
March 27, 2023 10:50 PM UTC
On the latest BioCentury This Week podcast, BioCentury’s editors assess responses to their VC survey regarding the collapse of Silicon Valley Bank in light of First Citizens’ acquisition of SVB. BioCentury’s editors also discuss how FDA’s advisory committee meeting for tofersen from Biogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) bolsters the case for NfL as a surrogate endpoint in amyotrophic lateral sclerosis (ALS) and why last week’s FDA draft guidance on accelerated approval could make cancer drug development harder for small biotechs.
This week’s podcast is sponsored by Jeito Capital. For information on how to sponsor BioCentury This Week and/or The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.